Eli Lilly & Co. (LLY) Financial Statements
Historical financial data — 42 statements covering FY2016–FY2025
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardianc...
Eli Lilly & Co.'s revenue increased 44.7% year over year, from $45.04B to $65.18B.
Net income increased 94.9% over the same period, from $10.59B to $20.64B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 207% in total.
Total debt increased by 26.3% to $42.50B.
The debt-to-equity ratio stands at 1.60, indicating a elevated leverage profile.
Operating cash flow grew 90.7% to $16.81B.
Eli Lilly & Co. maintains a strong net profit margin of 31.7%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $11.44B+1.2% | $970.3M | $9.27B | $1.59B | $3.71B | $75.61B | $31.12B | $14.24B |
| Q4 FY2024 | $13.53B+18.3% | $4.41B | $11.13B | $5.04B | $2.47B | $78.71B | $33.64B | $14.19B |
| Q1 FY2025 | $12.73B-5.9% | $2.76B | $10.50B | $3.46B | $1.67B | $89.39B | $38.52B | $15.76B |
| Q2 FY2025 | $15.56B+22.2% | $5.66B | $13.11B | $6.78B | $3.09B | $100.92B | $39.90B | $18.27B |
| Q3 FY2025 | $17.60B+13.1% | $5.58B | $14.59B | $7.23B | $8.84B | $114.94B | $42.51B | $23.79B |
| Q4 FY2025 | $19.29B+9.6% | $6.64B | $15.92B | $8.27B | $3.22B | $112.48B | $42.50B | $26.54B |
| Q1 FY2026 | $19.80B+2.6% | $7.40B | $16.22B | $8.85B | $5.33B | $116.58B | $43.37B | $31.20B |
| Q2 FY2026 | $22.97B+16.0% | $7.09B | $19.71B | $13.38B | $10.69B | $142.28B | $54.91B | $33.88B |
Balance Sheet Summary (Q2 FY2026)
Eli Lilly & Co. (LLY) Financial Statements & Revenue History
Eli Lilly & Co. (LLY) is a US-listed stock operating in the Healthcare sector, specifically the Drug Manufacturers - General industry trading at $1255.73 with a market capitalization of $1119. This page provides 42 historical financial statements for Eli Lilly & Co., including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Eli Lilly & Co. reported revenue of $65.2 billion, representing 44.7% year-over-year growth. The net profit margin of 31.7% reflects strong profitability. The debt-to-equity ratio of 1.60 indicates elevated leverage.
LLY Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Eli Lilly & Co.'s revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether LLY is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track LLY's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Eli Lilly & Co. converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of LLY's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use LLY Financial Data
Investors use Eli Lilly & Co.'s financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare LLY's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how LLY's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View LLY's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Eli Lilly & Co.'s SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.LLY trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.